Using personalized precision medicine to treat cognitive decline

Using personalized precision medicine to treat cognitive decline

Publication date: Aug 01, 2020

Affirmativ Health sought to determine whether a comprehensive and personalized program, designed to mitigate risk factors of Alzheimer’s disease could improve cognitive and metabolic function in individuals experiencing cognitive decline.

“The findings, published in the Journal of Alzheimer’s Disease Reports (Journal of Alzheimer’s Disease Reports 4(1)), are encouraging and indicate that a more extensive clinical study is warranted”, said Brian Kennedy, PhD, Director of The Centre for Healthy Aging, National University Health System, Singapore and Chief Scientific Officer, Affirmativ Health.

The Affirmativ Health scientific team, after thorough review of published research, has developed a comprehensive approach to addressing scientifically supported risk factors that have been rigorously defined as interventions to promote prevention, increased resiliency, and stabilization of brain function in the realm of AD and dementia.

The personalized therapeutic program includes genetics, an extensive blood panel, medical history and lifestyle data to evaluate relevant metabolic risk factors and nutrient levels associated with cognitive health.

“Target laboratory levels differ from standard laboratory ranges as the goal is to reach optimized levels for cognitive health”, Ginger Schechter, MD, Chief Medical Officer, Affirmativ Health The study approach considers more than 35 factors known to contribute to cognitive decline.

In conjunction with the publication of this vital study, and to expose alternative treatment options for Alzheimer’s disease and cognitive decline, the team at Affirmativ Health has written a book, Outsmart your Brain – an Insider’s Guide to Life-Long Memory.

Concepts Keywords
Aging Population Cardiovascular cancer
Alzheimer Complex systemic disease
Amyloid Cognitive disorders
Bankruptcy Psychiatric diagnosis
Blood Panel Psychiatry
Brain Learning disabilities
Brian Kennedy RTT
Cancer Neuroscience
Cardiovascular Cognition
Cognition Abnormal psychology
Cognitive Alzheimer’s disease
Cognitive Function Dementia
Precision Medicine
Risk Factor
Systemic Disease


Type Source Name
disease MESH cognitive decline
disease MESH risk factors
disease MESH aging
disease MESH chronic illnesses
disease MESH cause of death
disease MESH cardiovascular disease
disease MESH cancer
disease MESH Amyloid plaques
drug DRUGBANK Troleandomycin
disease MESH dementia
drug DRUGBANK Sulpiride
disease MESH lifestyle
disease MESH habits

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *